Literature DB >> 17377079

The effects of levosimendan in cardiac surgery patients with poor left ventricular function.

Stefan G De Hert1, Suraphong Lorsomradee, Stefanie Cromheecke, Philippe J Van der Linden.   

Abstract

BACKGROUND: Patients with poor left ventricular function often require inotropic drug support immediately after cardiopulmonary bypass. Levosimendan improves cardiac function by a novel mechanism of action compared to currently available drugs. We hypothesized that, in patients with severely compromised ventricular function, the use of levosimendan would be associated with better postoperative cardiac function than with inotropic drugs that increase myocardial oxygen consumption.
METHODS: Thirty patients with a preoperative ejection fraction < or =30% scheduled for elective cardiac surgery with cardiopulmonary bypass were randomized to two different inotropic protocols: milrinone 0.5 microg [corrected] x kg(-1) x min(-1) or levosimendan 0.1 microg [corrected] x kg(-1) x min(-1), started immediately after the release of the aortic crossclamp. The treatment was masked to the observers. All patients received dobutamine 5 microg [corrected] x kg(-1) x min(-1).
RESULTS: Stroke volume was similar between groups initially after surgery, but it declined 12 h after surgery in the milrinone group but not in the levosimendan group (P < 0.05 between groups) despite similar filling pressures. Total dose, duration of inotropic drug administration and norepinephrine dose were lower in the levosimendan group than in the milrinone group (P < 0.05). The duration of tracheal intubation was shorter in the former group compared with the milrinone group (P = 0008). Three patients in the milrinone group but none in the levosimendan group died within 30 days of surgery.
CONCLUSION: In cardiac surgery patients with a low preoperative ejection fraction, stroke volume was better maintained with the combination of dobutamine with levosimendan than with the combination of dobutamine with milrinone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17377079     DOI: 10.1213/01.ane.0000256863.92050.d3

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  38 in total

Review 1.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

Review 2.  Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.

Authors:  Geert Koster; Jørn Wetterslev; Christian Gluud; Jan G Zijlstra; Thomas W L Scheeren; Iwan C C van der Horst; Frederik Keus
Journal:  Intensive Care Med       Date:  2014-12-18       Impact factor: 17.440

3.  Comparison of Levosimendan, Milrinone and Dobutamine in treating Low Cardiac Output Syndrome Following Valve Replacement Surgeries with Cardiopulmonary Bypass.

Authors:  Mohd Yunus; Habib Md Reazaul Karim; Manuj Kumar Saikia; Prithwis Bhattacharyya; Samarjit Dey
Journal:  J Clin Diagn Res       Date:  2016-12-01

4.  Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.

Authors:  K Distelmaier; C Roth; L Schrutka; C Binder; B Steinlechner; G Heinz; I M Lang; G Maurer; H Koinig; A Niessner; M Hülsmann; W Speidl; G Goliasch
Journal:  Br J Anaesth       Date:  2016-07       Impact factor: 9.166

5.  Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.

Authors:  Bernard Cholley; Thibaut Caruba; Sandrine Grosjean; Julien Amour; Alexandre Ouattara; Judith Villacorta; Bertrand Miguet; Patrick Guinet; François Lévy; Pierre Squara; Nora Aït Hamou; Aude Carillion; Julie Boyer; Marie-Fazia Boughenou; Sebastien Rosier; Emmanuel Robin; Mihail Radutoiu; Michel Durand; Catherine Guidon; Olivier Desebbe; Anaïs Charles-Nelson; Philippe Menasché; Bertrand Rozec; Claude Girard; Jean-Luc Fellahi; Romain Pirracchio; Gilles Chatellier
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

Review 6.  Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery.

Authors:  Alexandre Mebazaa; Antonis A Pitsis; Alain Rudiger; Wolfgang Toller; Dan Longrois; Sven-Erik Ricksten; Ilona Bobek; Stefan De Hert; Georg Wieselthaler; Uwe Schirmer; Ludwig K von Segesser; Michael Sander; Don Poldermans; Marco Ranucci; Peter C J Karpati; Patrick Wouters; Manfred Seeberger; Edith R Schmid; Walter Weder; Ferenc Follath
Journal:  Crit Care       Date:  2010-04-28       Impact factor: 9.097

Review 7.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.

Authors:  Julia Schumann; Eva C Henrich; Hellen Strobl; Roland Prondzinsky; Sophie Weiche; Holger Thiele; Karl Werdan; Stefan Frantz; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

8.  Heart calcium sensitizer on morbidity and mortality of high-risk surgical patients with MODS: systematic review and meta-analysis.

Authors:  Li Qiao; Chengshan Xu; Xinji Li; Fei Li; Wei Liu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 9.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Newer treatments for decompensated heart failure: focus on levosimendan.

Authors:  Ferenc Follath
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.